Redeye briefly comments on the recent discussion surrounding the statistical power assumptions in Cinclus Pharma’s ongoing phase III HEEALIN...
Redeye briefly comments on Cinclus Pharma’s announcement that the last patient in the phase III HEEALING1 study with lead candidate linapraz...
Redeye provides a research update following the Q2 report published by Cinclus earlier today.
Redeye briefly comments on Cinclus’ announcement that patient screening has been successfully completed in the pivotal Phase III HEEALING1 s...
Redeye provides a research update following the Q1 report published by Cinclus earlier today.
Redeye leaves a comment following Cinclus’ announcement that it has secured a structured growth-debt financing facility of up to EUR28m from...
Redeye provides a research update following the Q4 report published by Cinclus earlier today.
Redeye leaves a short comment following Cinclus’ announcement of having received positive CMC feedback from the EMA for linaprazan glurate.
Redeye leaves a comment following Cinclus’ announcement that its lead candidate, linaprazan glurate, has been included on China’s 2025 Natio...
Redeye provides a research update following the Q3 report published by Cinclus earlier today.
Redeye briefly comments on Cinclus’ announcement that the first patient has been dosed in its pivotal phase III study with linaprazan glurat...
Redeye comments on Cinclus’ announcement that the first patient has been screened in its pivotal Phase III study with linaprazan glurate in ...
Redeye leaves a comment following Cinclus’ announcement earlier today of having initiated its phase III HEEALING 1 study in severe erosive G...
Redeye comments on Phathom Pharmaceuticals’ recent announcement that the FDA has approved its Citizen Petition, confirming extended market e...
Redeye comments on Cinclus Pharma’s announcement earlier today of a EUR220m licensing agreement with leading European pharmaceutical company...
Redeye comments on the Q4 report recently published by Cinclus Pharma’s peer, Phathom Pharmaceuticals.
Redeye leaves a comment following Cinclus’ announcement of linaprazan glurate having received market approval in China.
Redeye leaves a comment following Cinclus’ recent announcement that it has agreed on Paediatric Investigation Plan (PIP) with EMA.
Redeye leaves a short comment following Cinclus’ recent announcement that the manufacturing of the Investigational Medicinal Product (IMP), ...
Redeye initiates coverage of Cinclus Pharma, a Swedish biotech company offering a next-generation solution to the USD+5bn GERD treatment mar...
